Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia

Leukemia - United Kingdom
doi 10.1038/leu.2015.180
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Dual Targeting of eIF4E by Blocking MNK and mTOR Pathways in Leukemia

Cytokine
BiochemistryAllergyImmunologyHematologyMolecular Biology
2017English

Expanding Horizons in the Treatment of Mantle Cell Lymphoma: Ibrutinib a Novel BTK-targeting Inhibitor

International Journal of Basic & Clinical Pharmacology
2014English

The BTK Inhibitor Zanubrutinib (BGB-3111) Demonstrated Synergies With Other Anti-Lymphoma Targeted Agents

Haematologica
Hematology
2019English

Discovery of a Potent BTK Inhibitor With a Novel Binding Mode by Using Parallel Selections With a DNA-Encoded Chemical Library

ChemBioChem
Organic ChemistryBiochemistryMolecular MedicineMolecular Biology
2017English

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

English

Acalabrutinib (ACP-196): A Selective Second-Generation BTK Inhibitor

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2016English

Targeting BTK for the Treatment of FLT3-ITD Mutated Acute Myeloid Leukemia

Scientific Reports
Multidisciplinary
2015English

Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy